Indicators on Eprenetapopt You Should Know
Individual age is often a essential Consider deciding the eligibility of allo‐HSCT and the sort of conditioning program,The anti-PD1 antibody camrelizumab has long been used with A further epigenetic inhibitor decitabine in R/R HL and up to 71% patients received CR (Nie et al., 2019). Wang et al. conducted the stage II research to assess the secu